Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 250.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 210,000 shares of the biopharmaceutical company's stock after buying an additional 150,000 shares during the quarter. Prescott Group Capital Management L.L.C. owned about 0.39% of Emergent BioSolutions worth $2,008,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of EBS. SBI Securities Co. Ltd. acquired a new position in Emergent BioSolutions during the fourth quarter worth about $63,000. E Fund Management Co. Ltd. purchased a new position in Emergent BioSolutions in the 4th quarter valued at approximately $98,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions during the third quarter worth $96,000. FORA Capital LLC purchased a new stake in Emergent BioSolutions during the third quarter worth $103,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Emergent BioSolutions in the third quarter valued at $141,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on EBS. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, March 4th. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Remove Ads

Emergent BioSolutions Price Performance

EBS stock traded down $0.11 during trading on Tuesday, hitting $5.52. The stock had a trading volume of 1,372,106 shares, compared to its average volume of 2,637,167. The stock has a market cap of $299.67 million, a price-to-earnings ratio of -1.35 and a beta of 1.80. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company's 50 day moving average price is $9.25 and its two-hundred day moving average price is $8.91. Emergent BioSolutions Inc. has a 1-year low of $1.82 and a 1-year high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million for the quarter, compared to analysts' expectations of $254.67 million. During the same quarter last year, the firm earned ($0.77) earnings per share. On average, sell-side analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.